Multiple Sclerosis Drugs Market: Industry Analysis and forecast (2019 to 2027): By Drug Class, Route of Administration, Distribution Channel and Region

Multiple Sclerosis Drugs Market: Industry Analysis and forecast (2019 to 2027): By Drug Class, Route of Administration, Distribution Channel and Region

Market Scenario

Multiple Sclerosis Drugs Market was valued US$ XX Bn in 2018 and is expected to reach US$ XX Bn by 2027, at CAGR of XX% during forecast period of 2019 to 2027. Multiple sclerosis is a long lasting disease that can affect the spinal cord, brain, and the optic nerves in eyes. It can cause problems such as muscle control, vision, balance and other basic body functions. Multiple sclerosis also referred as disseminated sclerosis. At present, primary progressive multiple sclerosis market is facing lucrative growth because of the rising incidences of multiple sclerosis globally a patient awareness may promote the future growth of this market. The report study has analyzed revenue impact of covid-19 pandemic on the sales revenue of market leaders, market followers and disrupters in the report and same is reflected in our analysis. Multiple Sclerosis Drugs Market Drivers and Restrains Currently, numerous types of relapsing multiple sclerosis are gradually affecting the large number of populations globally, such as secondary-progressive multiple sclerosis (SPMS), relapsing remitting multiple sclerosis and progressive relapsing multiple sclerosis. According to multiple sclerosis web portal by United States and Health Union more than XX Mn people are affected by multiple sclerosis globally. Among the all different types of multiple sclerosis, XX % patients suffer from primary progressive multiple sclerosis. It is difficult to diagnose as well as treat these patients. Therefore, elevated demand for the advanced therapeutic treatment will fuel the growth of primary progressive multiple sclerosis (PPMS) market. The drugs used to treat multiple sclerosis are Interferon Beta (Avonex, Betaseron, Extavia, Plegridy, Rebif), Glatiramer Acetate (Copaxone, Glatopa), Fingolimod (Gilenya), Teriflunomide (Aubagio), Dimethyl Fumarate (Tecfidera) and others. The multiple sclerosis drug companies are increasing their offerings for interferon-β drugs, attributing to their efficiency for T cell leukemia associated with myelopathy, glioma, and tropical spastic par paresis. The hopeful results of multiple sclerosis drugs have also been addressed in fingolimod in intra cerebral hemorrhage and acute ischemic stroke. Therefore, ongoing research and development in the multiple sclerosis drugs market will lead to the arrival of innovative drugs for multiple sclerosis. Similarly, advances in multiple sclerosis drugs have led to effective medications for the relapsing and progressive forms of multiple sclerosis. In March 2019, Norvatis AG is Swiss multinational pharmaceutical company and a leading player operating in the multiple sclerosis drugs market announced the launch of the FDA approved multiple sclerosis drug such as Mayzent (siponimod), for the treatment of various multiple sclerosis conditions. Manufacturers in the Multiple Sclerosis Drugs are focusing on competitive pricing as the strategy to capture significant market share. Moreover, strategic mergers and acquisitions and technological innovations are also the key focus areas of the manufacturers. Multiple Sclerosis Drugs Market Segmentation Analysis The multiple sclerosis drugs market is segmented into four types such as drug class, route of administration, distribution channel and region. On the basis of route of administration, market is subdivided into oral and injection. The injection segment accounted for maximum profit in 2018, because of the active government recommendations and global market approvals. On the basis of drug class market is categorized into immunomodulators, immunosuppressants, interferons and others. In terms of distribution channels covered under the report are retail pharmacy, hospital pharmacy, and online stores. The immunomodulators used to diagnose Multiple Sclerosis such as glatiramer acetate, natalizumab, fingolimod, alemtuzumab, teriflunomide, and dimethyl fumarate (BG-12) and others. Biogen has occurred as a leading player in the multiple sclerosis drugs market because of the higher sales of Tecdera in 2018 and strategic partnership for increased distribution of drugs. Based on region, it is studied across Asia Pacific, North America, Europe, Latin America and Middle East Africa. Multiple Sclerosis Drugs Market Regional Analysis On the basis of region Multiple Sclerosis Drugs market divided into five region such as Asia Pacific, North America, Europe, Latin America, and Middle East Africa. Among all the regions, North America had hold the largest market share in 2018 and is projected to lead the market during the forecast period. Because of high incidence rates of multiple sclerosis and rising demands for therapeutic medications for the effective treatment of primary progressive multiple sclerosis in these regions. In recent studies of multiple sclerosis portal XX % people are affected by multiple sclerosis in Europe and XX % affected population is present in the United States. This can be credited to the higher sales of multiple sclerosis drugs in countries such as the United State and Canada. Furthermore, Asia Pacific is expected to expand at a comparatively high CAGR during the forecast period. The multiple sclerosis drugs market in Asia Pacific is driven by a large pool of patients with multiple sclerosis disease in China and Japan, launch and approval of new products, and growth in investments by leading players in the region in therapeutic drugs for multiple sclerosis disease. Therefore, the Asia Pacific is expected to be the second largest market over the forecast period and nearly follow by North America in terms of profits. The objective of the report is to present comprehensive analysis of Multiple Sclerosis Drugs Market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of industry with dedicated study of key players that includes market leaders, followers and new entrants by region. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors by region on the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give clear futuristic view of the industry to the decision makers. The report also helps in understanding Multiple Sclerosis Drugs Market dynamics, structure by analyzing the market segments, and project the Multiple Sclerosis Drugs Market size. Clear representation of competitive analysis of key players by Multiple Sclerosis Drugs Type, price, financial position, product portfolio, growth strategies, and regional presence in the Multiple Sclerosis Drugs Market make the report investor’s guide.

Scope of the Multiple Sclerosis Drugs Market

Multiple Sclerosis Drugs Market, by Drug Class

• Immunomodulators • Immunosuppressants • Interferons • Others

Multiple Sclerosis Drugs Market, By Route of Administration

• Oral • Injection

Multiple Sclerosis Drugs Market, Distribution Channel

• Hospital Pharmacies • Retail • Online Sales

Multiple Sclerosis Drugs Market, by Region

• Asia Pacific • North America • Europe • Latin America • Middle East Africa

Multiple Sclerosis Drugs Market, Major Players

• Norvatis AG • Allergan Plc. • Hoffmann-La Roche Ltd. • Astellas • Biocodex S A • Consumer Healthcare Inc. • Dainippon Sumitomo • ECR Pharmaceuticals • Eisai Co. • Flynn Pharma • Johnson and Johnson • Meda Consumer Healthcare Inc. • Merck and Co. Inc. • Neurim • Pernix Therapeutics • Pfizer Inc • Purdue Pharma L.P. • Sanofi Pasteur • SkyePharma • Takeda Pharmaceutical Company

Table of Contents

Multiple Sclerosis Drugs Market 1. Preface 1.1. Report Scope and Market Segmentation 1.2. Research Highlights 1.3. Research Objectives 2. Assumptions and Research Methodology 2.1. Report Assumptions 2.2. Abbreviations 2.3. Research Methodology 2.3.1. Secondary Research 2.3.1.1. Secondary data 2.3.1.2. Secondary Sources 2.3.2. Primary Research 2.3.2.1. Data from Primary Sources 2.3.2.2. Breakdown of Primary Sources 3. Executive Summary: Global Multiple Sclerosis Drugs Market Size, by Market Value (US$ Bn) 4. Market Overview 4.1. Introduction 4.2. Market Indicator 4.2.1. Drivers 4.2.2. Restraints 4.2.3. Opportunities 4.2.4. Challenges 4.3. Porter’s Analysis 4.4. Value Chain Analysis 4.5. Market Risk Analysis 4.6. SWOT Analysis 4.7. Industry Trends and Emerging Technologies 5. Supply Side and Demand Side Indicators 6. Global Multiple Sclerosis Drugs Market Analysis and Forecast 6.1. Global Multiple Sclerosis Drugs Market Size & Y-o-Y Growth Analysis 6.1.1. North America 6.1.2. Europe 6.1.3. Asia Pacific 6.1.4. Middle East & Africa 6.1.5. South America 7. Global Multiple Sclerosis Drugs Market Analysis and Forecast, by Drug Class 7.1. Introduction and Definition 7.2. Key Findings 7.3. Global Multiple Sclerosis Drugs Market Value Share Analysis, by Drug Class 7.4. Global Multiple Sclerosis Drugs Market Size (US$ Bn) Forecast, by Drug Class 7.5. Global Multiple Sclerosis Drugs Market Analysis, by Drug Class 7.6. Global Multiple Sclerosis Drugs Market Attractiveness Analysis, by Drug Class 8. Global Multiple Sclerosis Drugs Market Analysis and Forecast, by Route of Administration 8.1. Introduction and Definition 8.2. Key Findings 8.3. Global Multiple Sclerosis Drugs Market Value Share Analysis, by Route of Administration 8.4. Global Multiple Sclerosis Drugs Market Size (US$ Bn) Forecast, by Route of Administration 8.5. Global Multiple Sclerosis Drugs Market Analysis, by Route of Administration 8.6. Global Multiple Sclerosis Drugs Market Attractiveness Analysis, by Route of Administration 9. Global Multiple Sclerosis Drugs Market Analysis and Forecast, by Distribution Channel 9.1. Introduction and Definition 9.2. Key Findings 9.3. Global Multiple Sclerosis Drugs Market Value Share Analysis, by Distribution Channel 9.4. Global Multiple Sclerosis Drugs Market Size (US$ Bn) Forecast, by Distribution Channel 9.5. Global Multiple Sclerosis Drugs Market Analysis, by Distribution Channel 9.6. Global Multiple Sclerosis Drugs Market Attractiveness Analysis, by Distribution Channel 10. Global Multiple Sclerosis Drugs Market Analysis, by Region 10.1. Global Multiple Sclerosis Drugs Market Value Share Analysis, by Region 10.2. Global Multiple Sclerosis Drugs Market Size (US$ Bn) Forecast, by Region 10.3. Global Multiple Sclerosis Drugs Market Attractiveness Analysis, by Region 11. North America Multiple Sclerosis Drugs Market Analysis 11.1. Key Findings 11.2. North America Multiple Sclerosis Drugs Market Overview 11.3. North America Multiple Sclerosis Drugs Market Value Share Analysis, by Drug Class 11.4. North America Multiple Sclerosis Drugs Market Forecast, by Drug Class 11.4.1. Immunomodulators 11.4.2. Immunosuppressants 11.4.3. Interferons 11.4.4. Others 11.5. North America Multiple Sclerosis Drugs Market Value Share Analysis, by Route of Administration 11.6. North America Multiple Sclerosis Drugs Market Forecast, by Route of Administration 11.6.1. Oral 11.6.2. Injection 11.7. North America Multiple Sclerosis Drugs Market Value Share Analysis, by Distribution Channel 11.8. North America Multiple Sclerosis Drugs Market Forecast, by Distribution Channel 11.8.1. Hospital Pharmacies 11.8.2. Retail 11.8.3. Online Sales 11.9. North America Multiple Sclerosis Drugs Market Value Share Analysis, by Country 11.10. North America Multiple Sclerosis Drugs Market Forecast, by Country 11.10.1. U.S. 11.10.2. Canada 11.11. North America Multiple Sclerosis Drugs Market Analysis, by Country 11.12. U.S. Multiple Sclerosis Drugs Market Forecast, by Drug Class 11.12.1. Immunomodulators 11.12.2. Immunosuppressants 11.12.3. Interferons 11.12.4. Others 11.13. U.S. Multiple Sclerosis Drugs Market Forecast, by Route of Administration 11.13.1. Oral 11.13.2. Injection 11.14. U.S. Multiple Sclerosis Drugs Market Forecast, by Distribution Channel 11.14.1. Hospital Pharmacies 11.14.2. Retail 11.14.3. Online Sales 11.15. Canada Multiple Sclerosis Drugs Market Forecast, by Drug Class 11.15.1. Immunomodulators 11.15.2. Immunosuppressants 11.15.3. Interferons 11.15.4. Others 11.16. Steel Canada Multiple Sclerosis Drugs Market Forecast, by Route of Administration 11.16.1. Oral 11.16.2. Injection 11.17. Canada Multiple Sclerosis Drugs Market Forecast, by Distribution Channel 11.17.1. Hospital Pharmacies 11.17.2. Retail 11.17.3. Online Sales 11.18. North America Multiple Sclerosis Drugs Market Attractiveness Analysis 11.18.1. By Drug Class 11.18.2. By Route of Administration 11.18.3. By Distribution Channel 11.19. PEST Analysis 11.20. Key Trends 11.21. Key Developments 12. Europe Multiple Sclerosis Drugs Market Analysis 12.1. Key Findings 12.2. Europe Multiple Sclerosis Drugs Market Overview 12.3. Europe Multiple Sclerosis Drugs Market Value Share Analysis, by Drug Class 12.4. Europe Multiple Sclerosis Drugs Market Forecast, by Drug Class 12.4.1. Immunomodulators 12.4.2. Immunosuppressants 12.4.3. Interferons 12.4.4. Others 12.5. Europe Multiple Sclerosis Drugs Market Value Share Analysis, by Route of Administration 12.6. Europe Multiple Sclerosis Drugs Market Forecast, by Route of Administration 12.6.1. Oral 12.6.2. Injection 12.7. Europe Multiple Sclerosis Drugs Market Value Share Analysis, by Distribution Channel 12.8. Europe Multiple Sclerosis Drugs Market Forecast, by Distribution Channel 12.8.1. Hospital Pharmacies 12.8.2. Retail 12.8.3. Online Sales 12.9. Europe Multiple Sclerosis Drugs Market Value Share Analysis, by Country 12.10. Europe Multiple Sclerosis Drugs Market Forecast, by Country 12.10.1. Germany 12.10.2. U.K. 12.10.3. France 12.10.4. Italy 12.10.5. Spain 12.10.6. Rest of Europe 12.11. Europe Multiple Sclerosis Drugs Market Analysis, by Country 12.12. Germany Multiple Sclerosis Drugs Market Forecast, by Drug Class 12.12.1. Immunomodulators 12.12.2. Immunosuppressants 12.12.3. Interferons 12.12.4. Others 12.13. Germany Multiple Sclerosis Drugs Market Forecast, by Route of Administration 12.13.1. Oral 12.13.2. Injection 12.14. Germany Multiple Sclerosis Drugs Market Forecast, by Distribution Channel 12.14.1. Hospital Pharmacies 12.14.2. Retail 12.14.3. Online Sales 12.15. U.K. Multiple Sclerosis Drugs Market Forecast, by Drug Class 12.15.1. Immunomodulators 12.15.2. Immunosuppressants 12.15.3. Interferons 12.15.4. Others 12.16. U.K. Multiple Sclerosis Drugs Market Forecast, by Route of Administration 12.16.1. Oral 12.16.2. Injection 12.17. U.K. Multiple Sclerosis Drugs Market Forecast, by Distribution Channel 12.17.1. Hospital Pharmacies 12.17.2. Retail 12.17.3. Online Sales 12.18. France Multiple Sclerosis Drugs Market Forecast, by Drug Class 12.18.1. Immunomodulators 12.18.2. Immunosuppressants 12.18.3. Interferons 12.18.4. Others 12.19. France Multiple Sclerosis Drugs Market Forecast, by Route of Administration 12.19.1. Oral 12.19.2. Injection 12.20. France Multiple Sclerosis Drugs Market Forecast, by Distribution Channel 12.20.1. Hospital Pharmacies 12.20.2. Retail 12.20.3. Online Sales 12.21. Italy Multiple Sclerosis Drugs Market Forecast, by Drug Class 12.21.1. Immunomodulators 12.21.2. Immunosuppressants 12.21.3. Interferons 12.21.4. Others 12.22. Italy Multiple Sclerosis Drugs Market Forecast, by Route of Administration 12.22.1. Oral 12.22.2. Injection 12.23. Italy Multiple Sclerosis Drugs Market Forecast, by Distribution Channel 12.23.1. Hospital Pharmacies 12.23.2. Retail 12.23.3. Online Sales 12.24. Spain Multiple Sclerosis Drugs Market Forecast, by Drug Class 12.24.1. Immunomodulators 12.24.2. Immunosuppressants 12.24.3. Interferons 12.24.4. Others 12.25. Spain Multiple Sclerosis Drugs Market Forecast, by Route of Administration 12.25.1. Oral 12.25.2. Injection 12.26. Spain Multiple Sclerosis Drugs Market Forecast, by Distribution Channel 12.26.1. Hospital Pharmacies 12.26.2. Retail 12.26.3. Online Sales 12.27. Rest of Europe Multiple Sclerosis Drugs Market Forecast, by Drug Class 12.27.1. Immunomodulators 12.27.2. Immunosuppressants 12.27.3. Interferons 12.27.4. Others 12.28. Rest of Europe Multiple Sclerosis Drugs Market Forecast, by Route of Administration 12.28.1. Oral 12.28.2. Injection 12.29. Rest Of Europe Multiple Sclerosis Drugs Market Forecast, by Distribution Channel 12.29.1. Hospital Pharmacies 12.29.2. Retail 12.29.3. Online Sales 12.30. Europe Multiple Sclerosis Drugs Market Attractiveness Analysis 12.30.1. By Drug Class 12.30.2. By Route of Administration 12.30.3. By Distribution Channel 12.31. PEST Analysis 12.32. Key Trends 12.33. Key Developments 13. Asia Pacific Multiple Sclerosis Drugs Market Analysis 13.1. Key Findings 13.2. Asia Pacific Multiple Sclerosis Drugs Market Overview 13.3. Asia Pacific Multiple Sclerosis Drugs Market Value Share Analysis, by Drug Class 13.4. Asia Pacific Multiple Sclerosis Drugs Market Forecast, by Drug Class 13.4.1. Immunomodulators 13.4.2. Immunosuppressants 13.4.3. Interferons 13.4.4. Others 13.5. Asia Pacific Multiple Sclerosis Drugs Market Value Share Analysis, by Route of Administration 13.6. Asia Pacific Multiple Sclerosis Drugs Market Forecast, by Route of Administration 13.6.1. Oral 13.6.2. Injection 13.7. Asia Pacific Multiple Sclerosis Drugs Market Value Share Analysis, by Distribution Channel 13.8. Asia Pacific Multiple Sclerosis Drugs Market Forecast, by Distribution Channel 13.8.1. Hospital Pharmacies 13.8.2. Retail 13.8.3. Online Sales 13.9. Asia Pacific Multiple Sclerosis Drugs Market Value Share Analysis, by Country 13.10. Asia Pacific Multiple Sclerosis Drugs Market Forecast, by Country 13.10.1. China 13.10.2. India 13.10.3. Japan 13.10.4. ASEAN 13.10.5. Rest of Asia Pacific 13.11. Asia Pacific Multiple Sclerosis Drugs Market Analysis, by Country 13.12. China Multiple Sclerosis Drugs Market Forecast, by Drug Class 13.12.1. Immunomodulators 13.12.2. Immunosuppressants 13.12.3. Interferons 13.12.4. Others 13.13. China Multiple Sclerosis Drugs Market Forecast, by Route of Administration 13.13.1. Oral 13.13.2. Injection 13.14. China Multiple Sclerosis Drugs Market Forecast, by Distribution Channel 13.14.1. Hospital Pharmacies 13.14.2. Retail 13.14.3. Online Sales 13.15. India Multiple Sclerosis Drugs Market Forecast, by Drug Class 13.15.1. Immunomodulators 13.15.2. Immunosuppressants 13.15.3. Interferons 13.15.4. Others 13.16. India Multiple Sclerosis Drugs Market Forecast, by Route of Administration 13.16.1. Oral 13.16.2. Injection 13.17. India Multiple Sclerosis Drugs Market Forecast, by Distribution Channel 13.17.1. Hospital Pharmacies 13.17.2. Retail 13.17.3. Online Sales 13.18. Japan Multiple Sclerosis Drugs Market Forecast, by Drug Class 13.18.1. Immunomodulators 13.18.2. Immunosuppressants 13.18.3. Interferons 13.18.4. Others 13.19. Japan Multiple Sclerosis Drugs Market Forecast, by Route of Administration 13.19.1. Oral 13.19.2. Injection 13.20. Japan Multiple Sclerosis Drugs Market Forecast, by Distribution Channel 13.20.1. Hospital Pharmacies 13.20.2. Retail 13.20.3. Online Sales 13.21. ASEAN Multiple Sclerosis Drugs Market Forecast, by Drug Class 13.21.1. Immunomodulators 13.21.2. Immunosuppressants 13.21.3. Interferons 13.21.4. Others 13.22. ASEAN Multiple Sclerosis Drugs Market Forecast, by Route of Administration 13.22.1. Oral 13.22.2. Injection 13.23. ASEAN Multiple Sclerosis Drugs Market Forecast, by Distribution Channel 13.23.1. Hospital Pharmacies 13.23.2. Retail 13.23.3. Online Sales 13.24. Rest of Asia Pacific Multiple Sclerosis Drugs Market Forecast, by Drug Class 13.24.1. Immunomodulators 13.24.2. Immunosuppressants 13.24.3. Interferons 13.24.4. Others 13.25. Rest of Asia Pacific Multiple Sclerosis Drugs Market Forecast, by Route of Administration 13.25.1. Oral 13.25.2. Injection 13.26. Rest of Asia Pacific Multiple Sclerosis Drugs Market Forecast, by Distribution Channel 13.26.1. Hospital Pharmacies 13.26.2. Retail 13.26.3. Online Sales 13.27. Asia Pacific Multiple Sclerosis Drugs Market Attractiveness Analysis 13.27.1. By Drug Class 13.27.2. By Route of Administration 13.27.3. By Distribution Channel 13.28. PEST Analysis 13.29. Key Trends 13.30. Key Developments 14. Middle East & Africa Multiple Sclerosis Drugs Market Analysis 14.1. Key Findings 14.2. Middle East & Africa Multiple Sclerosis Drugs Market Overview 14.3. Middle East & Africa Multiple Sclerosis Drugs Market Value Share Analysis, by Drug Class 14.4. Middle East & Africa Multiple Sclerosis Drugs Market Forecast, by Drug Class 14.4.1. Immunomodulators 14.4.2. Immunosuppressants 14.4.3. Interferons 14.4.4. Others 14.5. Middle East & Africa Multiple Sclerosis Drugs Market Value Share Analysis, by Route of Administration 14.6. Middle East & Africa Multiple Sclerosis Drugs Market Forecast, by Route of Administration 14.6.1. Oral 14.6.2. Injection 14.7. Middle East & Africa Multiple Sclerosis Drugs Market Value Share Analysis, by Distribution Channel 14.8. Middle East & Africa Multiple Sclerosis Drugs Market Forecast, by Distribution Channel 14.8.1. Hospital Pharmacies 14.8.2. Retail 14.8.3. Online Sales 14.9. Middle East & Africa Multiple Sclerosis Drugs Market Value Share Analysis, by Country 14.10. Middle East & Africa Multiple Sclerosis Drugs Market Forecast, by Country 14.10.1. GCC 14.10.2. South Africa 14.10.3. Rest of Middle East & Africa 14.11. Middle East & Africa Multiple Sclerosis Drugs Market Analysis, by Country 14.12. GCC Multiple Sclerosis Drugs Market Forecast, by Drug Class 14.12.1. Immunomodulators 14.12.2. Immunosuppressants 14.12.3. Interferons 14.12.4. Others 14.13. GCC Multiple Sclerosis Drugs Market Forecast, by Route of Administration 14.13.1. Oral 14.13.2. Injection 14.14. GCC Multiple Sclerosis Drugs Market Forecast, by Distribution Channel 14.14.1. Hospital Pharmacies 14.14.2. Retail 14.14.3. Online Sales 14.15. South Africa Multiple Sclerosis Drugs Market Forecast, by Drug Class 14.15.1. Immunomodulators 14.15.2. Immunosuppressants 14.15.3. Interferons 14.15.4. Others 14.16. South Africa Multiple Sclerosis Drugs Market Forecast, by Route of Administration 14.16.1. Oral 14.16.2. Injection 14.17. South Africa Multiple Sclerosis Drugs Market Forecast, by Distribution Channel 14.17.1. Hospital Pharmacies 14.17.2. Retail 14.17.3. Online Sales 14.18. Rest of Middle East & Africa Multiple Sclerosis Drugs Market Forecast, by Drug Class 14.18.1. Immunomodulators 14.18.2. Immunosuppressants 14.18.3. Interferons 14.18.4. Others 14.19. Rest of Middle East & Africa Multiple Sclerosis Drugs Market Forecast, by Route of Administration 14.19.1. Oral 14.19.2. Injection 14.19.3. Retail 14.19.4. Education 14.19.5. Banking 14.19.6. Medical and industrial 14.20. Rest of Middle East & Africa Multiple Sclerosis Drugs Market Forecast, by Distribution Channel 14.20.1. Hospital Pharmacies 14.20.2. Retail 14.20.3. Online Sales 14.21. Middle East & Africa Multiple Sclerosis Drugs Market Attractiveness Analysis 14.21.1. By Drug Class 14.21.2. By Route of Administration 14.21.3. By Distribution Channel 14.22. PEST Analysis 14.23. Key Trends 14.24. Key Developments 15. South America Multiple Sclerosis Drugs Market Analysis 15.1. Key Findings 15.2. South America Multiple Sclerosis Drugs Market Overview 15.3. South America Multiple Sclerosis Drugs Market Value Share Analysis, by Drug Class 15.4. South America Multiple Sclerosis Drugs Market Forecast, by Drug Class 15.4.1. Immunomodulators 15.4.2. Immunosuppressants 15.4.3. Interferons 15.4.4. Others 15.5. South America Multiple Sclerosis Drugs Market Value Share Analysis, by Route of Administration 15.6. South America Multiple Sclerosis Drugs Market Forecast, by Route of Administration 15.6.1. Oral 15.6.2. Injection 15.7. South America Multiple Sclerosis Drugs Market Value Share Analysis, by Distribution Channel 15.8. South America Multiple Sclerosis Drugs Market Forecast, by Distribution Channel 15.8.1. Hospital Pharmacies 15.8.2. Retail 15.8.3. Online Sales 15.9. South America Multiple Sclerosis Drugs Market Value Share Analysis, by Country 15.10. South America Multiple Sclerosis Drugs Market Forecast, by Country 15.10.1. Brazil 15.10.2. Mexico 15.10.3. Rest of South America 15.11. South America Multiple Sclerosis Drugs Market Analysis, by Country 15.12. Brazil Multiple Sclerosis Drugs Market Forecast, by Drug Class 15.12.1. Immunomodulators 15.12.2. Immunosuppressants 15.12.3. Interferons 15.12.4. Others 15.13. Brazil Multiple Sclerosis Drugs Market Forecast, by Route of Administration 15.13.1. Oral 15.13.2. Injection 15.14. Brazil Multiple Sclerosis Drugs Market Forecast, by Distribution Channel 15.14.1. Hospital Pharmacies 15.14.2. Retail 15.14.3. Online Sales 15.15. Mexico Multiple Sclerosis Drugs Market Forecast, by Drug Class 15.15.1. Immunomodulators 15.15.2. Immunosuppressants 15.15.3. Interferons 15.15.4. Others 15.16. Mexico Multiple Sclerosis Drugs Market Forecast, by Route of Administration 15.16.1. Oral 15.16.2. Injection 15.17. Mexico Multiple Sclerosis Drugs Market Forecast, by Distribution Channel 15.17.1. Hospital Pharmacies 15.17.2. Retail 15.17.3. Online Sales 15.18. Rest of South America Multiple Sclerosis Drugs Market Forecast, by Drug Class 15.18.1. Immunomodulators 15.18.2. Immunosuppressants 15.18.3. Interferons 15.18.4. Others 15.19. Rest of South America Multiple Sclerosis Drugs Market Forecast, by Route of Administration 15.19.1. Oral 15.19.2. Injection 15.20. Rest of South America Multiple Sclerosis Drugs Market Forecast, by Distribution Channel 15.20.1. Hospital Pharmacies 15.20.2. Retail 15.20.3. Online Sales 15.21. South America Multiple Sclerosis Drugs Market Attractiveness Analysis 15.21.1. By Drug Class 15.21.2. By Route of Administration 15.21.3. By Distribution Channel 15.22. PEST Analysis 15.23. Key Trends 15.24. Key Developments 16. Company Profiles 16.1. Market Share Analysis, by Company 16.2. Competition Matrix 16.2.1. Competitive Benchmarking of key players by price, presence, market share, Applications and R&D investment 16.2.2. New Product Launches and Product Enhancements 16.2.3. Market Consolidation 16.2.3.1. M&A by Regions, Investment and Applications 16.2.3.2. M&A Key Players, Forward Integration and Backward Integration 16.3. Company Profiles: Key Players 16.3.1. Norvatis AG 16.3.1.1. Company Overview 16.3.1.2. Financial Overview 16.3.1.3. Portfolio 16.3.1.4. Business Strategy 16.3.1.5. Recent Developments 16.3.1.6. Development Footprint 16.3.2. Astellas 16.3.3. Consumer Healthcare Inc. 16.3.4. Dainippon Sumitomo 16.3.5. ECR Pharmaceuticals 16.3.6. Eisai Co. 16.3.7. Flynn Pharma 16.3.8. Johnson and Johnson 16.3.9. Meda Consumer Healthcare Inc. 16.3.10. Merck and Co. Inc. 16.3.11. Neurim 16.3.12. Pernix Therapeutics 16.3.13. Pfizer Inc 16.3.14. Purdue Pharma L.P. 16.3.15. Sanofi Pasteur 16.3.16. SkyePharma 16.3.17. Takeda Pharmaceutical Company 17. Primary Key Insights

About This Report

Report ID39309
Category Healthcare
Published DateDec 2019
No of Pages195
Contact Us
Call Now